Key result
Ticagrelor dose-dependently augmented reactive hyperemia and intracoronary adenosine-induced increases in left anterior descending blood flow relative to control (P < .05).
Why the study?
Does ticagrelor inhibit adenosine uptake and enhance adenosine-mediated hyperemia in a canine model?
Population
Purified human erythrocytes, cell lines, and an open-chest dog model
Comparison
Ticagrelor vs Dipyridamole or vehicle
Design
Preclinical
Authors
Loading...
Ticagrelor may potentiate adenosine responses via uptake inhibition; leaves open contribution to clinical effects or side effects.
Does ticagrelor inhibit adenosine uptake and enhance adenosine-mediated hyperemia in a canine model?
p-value: p=< .05
Ticagrelor inhibits adenosine uptake and augments cardiac blood flow in a canine model, suggesting potential pleiotropic benefits beyond platelet inhibition.
Giezen et al. (2011) studied None (animal model) (n=24). Ticagrelor vs. Vehicle and dipyridamole was evaluated on Left anterior descending (LAD) coronary artery blood flow during reactive hyperemia or intracoronary infusion of adenosine (p=< .05). Ticagrelor dose-dependently augmented reactive hyperemia and intracoronary adenosine-induced increases in left anterior descending blood flow relative to control (P < .05).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: